Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease

Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease

NCT02176187 ·Status: TERMINATED ·Phase: PHASE3

Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02173782 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.

NCT00267917 ·Status: COMPLETED ·Phase: PHASE4

Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02176200 ·Status: TERMINATED ·Phase: PHASE3

Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease

NCT02244216 ·Status: COMPLETED

Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00153075 ·Status: COMPLETED ·Phase: PHASE4

Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

NCT02233894 ·Status: COMPLETED

Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

NCT02238171 ·Status: COMPLETED

Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

NCT02233881 ·Status: COMPLETED

Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease

NCT02238197 ·Status: COMPLETED

Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease

NCT02238145 ·Status: COMPLETED

Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD

NCT02567214 ·Status: COMPLETED ·Phase: PHASE4

Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02236169 ·Status: COMPLETED ·Phase: PHASE2

Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events

NCT02096731 ·Status: COMPLETED

Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis

NCT02233920 ·Status: COMPLETED

Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease

NCT02260011 ·Status: COMPLETED ·Phase: PHASE2

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

NCT04078126 ·Status: COMPLETED ·Phase: PHASE3

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

NCT01019694 ·Status: COMPLETED ·Phase: PHASE3

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

NCT02138916 ·Status: COMPLETED ·Phase: PHASE3

Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

NCT02236715 ·Status: COMPLETED

Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

NCT02238158 ·Status: COMPLETED

Budesonide / Formoterol in Treatment of Exacerbations of COPD

NCT00239278 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

NCT06297668 ·Status: COMPLETED ·Phase: PHASE1

Inhaled Bronchodilator Association and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease

NCT02176564 ·Status: COMPLETED

Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT00665600 ·Status: COMPLETED ·Phase: PHASE3